医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

ropeginterferon alfa-2b-njft

PharmaEssentia’s BESREMi (ropeginterferon alfa-2b-njft) Now Recommended as a Preferred First-line Cytoreductive Therapy for Polycythemia Vera in Updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)

PharmaEssentia’s BESREMi (ropeginterferon alfa-2b-njft) Now Recommended as a Preferred First-line Cytoreductive Therapy for Polycythemia Vera in Updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: NCCN Guidelines Now Recommended as a Preferred First-line Cytoreductive Therapy for Polycythemia Vera in Updated NCCN Clinical Practice Guidelines in Oncology PharmaEssentia’s BESREMi ropeginterferon alfa-2b-njft

2024年02月28日

PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi® (ropeginterferon alfa-2b-njft) in Latin America

PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi® (ropeginterferon alfa-2b-njft) in Latin America

その他ヘルスバイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: in Latin America PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi ropeginterferon alfa-2b-njft

2023年06月02日

PharmaEssentia Honored at the National Organization of Rare Disorders (NORD®) 2022 Rare Impact Awards for the Introduction of BESREMi® (ropeginterferon alfa-2b-njft) for Polycythemia Vera

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: NORD ropeginterferon alfa-2b-njft

2022年06月22日

PharmaEssentia’s BESREMi® (ropeginterferon alfa-2b-njft) Now Available for the Treatment of People With Polycythemia Vera in the United States

PharmaEssentia’s BESREMi® (ropeginterferon alfa-2b-njft) Now Available for the Treatment of People With Polycythemia Vera in the United States

ヘルスケア腫瘍学製薬　 TimeLine: Now Available for the Treatment of People With Polycythemia Vera in the United States PharmaEssentia’s BESREMi ropeginterferon alfa-2b-njft

2021年12月06日

U.S. FDA Approves BESREMi® (ropeginterferon alfa-2b-njft) as the Only Interferon for Adults With Polycythemia Vera

U.S. FDA Approves BESREMi® (ropeginterferon alfa-2b-njft) as the Only Interferon for Adults With Polycythemia Vera

その他ヘルスバイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: as the Only Interferon for Adults With Polycythemia Vera FDA Approves BESREMi ropeginterferon alfa-2b-njft

2021年11月13日